2009
DOI: 10.1167/iovs.09-3525
|View full text |Cite
|
Sign up to set email alerts
|

Effects of an Antagonist of the Gastrin-Releasing Peptide Receptor in an Animal Model of Uveitis

Abstract: These findings suggest that GRP participates in the inflammatory response in an animal model of uveitis, making GRPR a target for new therapeutic options in the treatment of uveitis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
9
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 31 publications
2
9
0
Order By: Relevance
“…RC‐3095 has been tested in an animal model of sepsis, in which the treatment was shown to decrease the production of proinflammatory cytokines, such as TNFα and IL‐1β, without changing the production of the antiinflammatory cytokine IL‐10, leading to improved survival of the treated animals (17). In an animal model of uveitis, RC‐3095 elicited important action against oxidative damage in the irides, and also exhibited antiinflammatory actions by reducing the activity of myeloperoxidase and decreasing the levels of TNFα and MCP‐1 to a higher extent than that with dexamethasone (18). In an animal model of gastric ulcer, RC‐3095 treatment, administered alone or in combination with omeprazole, was effective for the inhibition of acid secretion, in addition to exerting protective effects by reducing gastric oxidative injury (19).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…RC‐3095 has been tested in an animal model of sepsis, in which the treatment was shown to decrease the production of proinflammatory cytokines, such as TNFα and IL‐1β, without changing the production of the antiinflammatory cytokine IL‐10, leading to improved survival of the treated animals (17). In an animal model of uveitis, RC‐3095 elicited important action against oxidative damage in the irides, and also exhibited antiinflammatory actions by reducing the activity of myeloperoxidase and decreasing the levels of TNFα and MCP‐1 to a higher extent than that with dexamethasone (18). In an animal model of gastric ulcer, RC‐3095 treatment, administered alone or in combination with omeprazole, was effective for the inhibition of acid secretion, in addition to exerting protective effects by reducing gastric oxidative injury (19).…”
Section: Discussionmentioning
confidence: 99%
“…The pseudononapeptide RC‐3095 is an antagonist of the receptor of bombesin/GRP, originally synthesized by McKillop et al in 1990 (16), with the aim of inhibiting the action of bombesin/GRP. Using this specific antagonist of the GRPR, our group has demonstrated that inhibition of the GRPR could decrease the release of TNFα and IL‐1β from activated macrophages in an experimental model of sepsis (17), elicit important action against oxidative damage in an experimental model of uveitis (18), and protect against gastric oxidative injury in an animal model of gastritis (19).…”
mentioning
confidence: 99%
“…Evidence supports a role for Bn related peptides and their receptors in a wide spectrum of inflammatory processes including gastritis [263,264,266,288], uveitis [260,264,266], arthritis [98,100,10,251,252,264,266], small intestinal or colonic inflammation [5,12,104,264,266], experimental sepsis [52,61,264,266,267], acute lung inflammation and injury [59,65,264,266,266,341] and gastrointestinal inflammation [10,151,264,266]. These studies suggest BnRs plays different roles in these processes because in some inflammatory processes Bn/GRP is protective and ameliorates the damage from various noxious agents in the stomach, small intestine and in the colon [5,9,12,104,264,266,284], whereas in other inflammatory conditions of the colon or lung, either Bn/GRP stimulate the inflammation or Bn/GRP antagonists ameliorate the inflammation [59,62,65,260,264,266,341,382]. In the latter case a number of studies support the conclusion that activation of GRPR due to increased release of bombesin like peptides from pulmonary neuroendocrine cells is a common denominator for a number of lung diseases, particularly those associated with decreased alveolarization, including both bronchopulmonary dysplasia and emphysema [59,65,266,341].…”
Section: Bnr Function In Disease and A Therapeutic Target (Table 3)mentioning
confidence: 99%
“…22 Two hours after LPS administration, saline, prednisolone acetate 1% (Latinofarma Pharmaceutical Industries, Cotia, Brazil), GS (aurochloric acid 2 mM) and GNP (40 mg/mL) were topically applied to both eyes of rats and repeated every 6 hours for 24 hours. Both GS and GNP were prepared under sterile conditions as isotonic solutions.…”
Section: Eiu and Treatmentsmentioning
confidence: 99%